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Diabetes-induced glomerular dysfunction: Links to a more reduced
cytosolic ratio of NADH/NAD. These studies were undertaken to
examine effects of elevated glucose levels on glycolysis, sorbitol
pathway activity, and the cytosolic redox state of NADH/NAD in
isolated glomeruli. Blood-free glomeruli were isolated from kidneys of
male, Sprague-Dawley rats using standard sieving techniques, then
incubated for one hour at 37°C, pH 7.4, P°2 --500 torr, in Krebs
bicarbonate/Hepes buffer containing 5 or 30 m glucose. Elevated
glucose levels increased glucose 6-phosphate, fructose 6-phosphate,
total triose phosphates, lactate, the lactate/pyruvate ratio, sorbitol, and
fructose, but did not affect sn-glycerol 3-phosphate, pyruvate, or
myo-inositol levels. The more reduced glomerular cytosolic redox state
(manifested by the tissue lactate/pyruvate ratio) induced by 30 mM
glucose was completely abrogated by aldose reductase inhibitors added
to the diet two to seven days prior to glomerular isolation. These
observations, coupled with evidence linking glucose- and diabetes-
induced glomerular dysfunction to increased sorbitol pathway metabo-
lism, support the hypothesis that metabolic imbalances associated with
a more reduced ratio of cytosolic NADH/NAD (resulting from in-
creased glucose metabolism via the sorbitol pathway) play an important
role in mediating glucose- and diabetes-induced glomerular dysfunc-
tion.
Glomerular dysfunction is readily demonstrable in humans
and in animals shortly after the onset of poorly controlled
diabetes [1—61. These glomerular changes, manifested as in-
creases in blood flow, GFR, and microalbuminuria, together
with associated increases in blood flow and/or vascular albumin
permeation in ocular tissues, sciatic nerve, and aorta of diabetic
rats, have been linked to increased metabolism of glucose via
the sorbitol pathway by many [5—Il] but not all [12] investiga-
tors. Increased GFR in human diabetics also is attenuated by
treatment with an inhibitor of aldose reductase [13]. The precise
nature of the metabolic imbalances that mediate sorbitol path-
way-linked glomerular and other vascular (and neural) dysfunc-
tion, however, remains unclear.
Topical application of glucose or sorbitol to newly formed
granulation tissue vessels in skin chambers increases vascular
albumin permeation and blood flow in nondiabetie rats to levels
observed in diabetic rats, but in the absence of insulin defi-
ciency and associated systemic hormonal and metabolic imbal-
ances characteristic of the diabetic milieu [6, 14]. As shown in
Figure 1, these glucose-induced vascular changes are prevented
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by coadministration of: 1) pyruvate [15—17] which also prevents
associated increases in tissue levels of I ,2-diacyl-sn-glycerol
(DAG) in extracts of granulation tissue [15]; 2) inhibitors of
aldose reductase [14] which also prevent glucose-induced in-
creases in the ratio of lactate/pyruvate [18] (the most reliable
parameter of cytosolic NADH/NAD [19]); 3) staurosporine
[15], an inhibitor of protein kinase C; and 4) myo-inositol [17].
The mechanism by which myo-inositol prevents sorbitol path-
way-linked vascular dysfunction remains unclear. Taken to-
gether, these observations suggest that glucose-induced vascu-
lar dysfunction is linked to elevated tissue levels of DAG and
associated activation of protein kinase C [15] resulting from a
more reduced cytosolic ratio of NADH/NAD. This redox
change results from increased oxidation of sorbitol to fructose
which is coupled to reduction of NAD to NADH (Fig. 1) [6,
11].
Glucose-induced increased de novo synthesis of DAG, in-
creased tissue levels of DAG, and associated activation of
protein kinase C also have been observed in isolated glomeruli
[20, 21] and in cultured bovine retinal capillary endothelial cells
[22, 23]; an increase in DAG mass has been reported in whole
retina and in myocardium of diabetic rats [22, 241; and activa-
tion of protein kinase C has been observed in bovine aortic
smooth muscle cells and endothelial cells exposed to elevated
glucose levels in vitro [22]. A more reduced cytosolic ratio of
NADH/NAD could promote increased de novo synthesis of
DAG through two mechanisms (Fig. I). First, it would favor
reduction of dihydroxyacetone phosphate (DHAP) to sn-glyc-
erol 3-phosphate (snG3P), the first step in the pathway for de
novo synthesis of DAG. Second, it would tend to increase the
availability of substrate (DHAP) by impairing oxidation of
glyceraldehyde 3-phosphate (GAP) to I ,3-bisphosphoglycerate
(1,3 DPG). Evidence of a more reduced cytosolic ratio of
NADH/NAD has been observed in a variety of tissues of
diabetic animals as well as in cells and tissues exposed to
elevated glucose levels in vitro [6, 18, 19, 25—27].
In light of these considerations, the present studies were
undertaken to examine effects on isolated glomeruli of elevated
glucose levels in vitro on cytosolic NADH/NAD reflected by
the lactate/pyruvate ratio. The likelihood that acute glucose-
induced in vitro metabolic imbalances of this nature may
mediate increased GFR in diabetic subjects is supported by
evidence that GFR is acutely increased in human subjects and
in nondiabetic animals by brief intravascular infusion of glucose
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Fig. 1. Interrelated metabolic imbalances linked to glucose- and diabetes-induced vascular dysfunction. *pharmacologic interventions which
prevent glucose-induced vascular dysfunction are indicated by an asterisk and include: aldose reductase inhibitors (ARI), aminoguanidine (AG),
staurosporine (stauro), pyruvate, myo-inositol (myo), diphenhydramine (DPH), and acetyl-L-carnitine (Acetyl-L-C). snG3P = sn-glycerol
3-phosphate, FA = free fatty acid, GA = glyceraldehyde, LcAcyl-C = long-chainacylcarnitine, LcAcyl-CoA = long-chain acyl coenzyme A, NEG
= nonenzymatic glycation, PKC = protein kinase C, P1 = phosphatidylinositol. Substances which ,ni,nic glucose effects on vascular function are
italicized and underlined. See references [6, 111 for further discussion of the effects of pharmacologic agents depicted in this figure.
[28, 29] or of lactate [30]. Lactate infusion would increase intra-
and extracellular lactate/pyruvate ratios resulting in a more
reduced cytosolic ratio of NADH/NAD and hindering oxida-
tion of NADH to NAD (coupled to reduction of pyruvate to
lactate).
Methods
Animal protocols
All rats used in these experiments were housed and cared for
in accordance with the guidelines of the University Committee
for the Humane Care of Laboratory Animals and in accordance
with NIH guidelines on laboratory animal welfare. Rats were
housed individually, allowed food and water ad libitum, and
were on a 12-hour light/dark cycle. Glomeruli were obtained
from kidneys of normal male, Sprague-Dawley rats weighing
—250 g.
Glomerular isolation protocols
For each glomerular isolation, five male Sprague-Dawley rats
were anesthetized with sodium pentobarbital (35 to 45 mg/kg
body weight) and anticoagulated with sodium heparin (2000
units i.p.) 10 to 15 minutes prior to surgery. A midline abdom-
inal incision was made to expose both kidneys as well as the
aorta and vena cava distal to the renal arteries. The aorta was
occluded proximal to the renal arteries, a 21-gauge needle
(attached to a 30 ml syringe) was inserted into the abdominal
aorta below the renal arteries, a cut was made in the vena cava
at the level of the renal arteries, and both kidneys were perfused
by hand with —20 ml of Krebs bicarbonate/Hepes (KH) buffer
(containing in mM: NaCI, 16; KCI, 5.4; CaCI2 2H20, 1.8;
NaH2PO4• H20, 1.0; MgSO4 - 7H20, 0.8; NaHCO3, 15.0; glu-
cose, 5.0; and Hepes, 18.0), pH 7.4, 4°C. Both kidneys
blanched within seconds after initiation of buffer perfusion and
were moved —20 seconds later and placed in a beaker contain-
ing KH buffer on ice. Immediately following the removal of
kidneys from five rats, the capsules were stripped from all
kidneys, medullary tissue was removed and discarded, and the
pooled cortical tissue was minced on a ice-chilled cutting block
into a fine paste with a razor blade. Glomeruli were isolated by
sequential sieving at room temperature through three stainless
steel sieves prewet with the KH buffer as described by Schlon-
dorif et al [31]. The 8-inch diameter sieves were (from top to
bottom) a Tyler equivalent 100 mesh (pore size 150 tm), a Tyler
equivalent 170 mesh (pore size 90 /rm), and a Tyler equivalent
270 mesh (pore size 53 /rm). The cortical paste was gently
forced through each sieve using the bottom of a 200 ml glass
beaker and 2 to 3 liters of the KH buffer at room temperature for
each sieve.
Glomeruli were flushed into a 50-mi conical bottom polypro-
pylene tube using KH buffer and centrifuged for one minute at
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200 rpm. The supernatant was removed and the glomeruli were
resuspended in 10 ml of KH buffer containing 0.05% bovine
serum albumin and 75 M myo-inositol (incubation buffer).
After gassing with 95% 02 and 5% CO2 (P02, --500 torr) at
37°C, the glomeruli were allowed to rest for IS minutes. The
glomeruli were then centrifuged (2000 rpm for 30 seconds), the
supernatant was removed, and the glomerular pellet was resus-
pended in fresh incubation buffer in a total volume of --2.6 ml.
Six hundred microliter aliquots of well-mixed glomerular sus-
pension (20,000 to 30,000 glomeruli) were added to four 5-mi
sialinized vacutainer tubes in a 37°C (shaking) water bath. Five
IO-pi samples were removed for glomerular counting and to
check their purity by light microscopy. The mean ratio of
glomeruli to tubular fragments for all preparations was 15:1 with
a standard deviation of 2.6%. After addition of substrates (in a
volume of 25 1uJ), the tubes were gassed with humidified 95% 02
and 5% CO2 for five minutes and then tightly capped and
incubated for one hour at 37°C.
Experimental protocols
In the first set of preliminary experiments, glomeruli were
incubated in 5 or 50 m glucose for 30, 60, or 120 minutes or in
5, 15, or 30 m glucose for 60 minutes. Incubations were
terminated by rapidly adding 60 irl of 12 N perchloric acid to the
incubation buffer with shaking and the extract (tissue + me-
dium) was saved for measurement of glycolytic intermediates.
In the second series of experiments, glomeruli were incubated
in 5 or 30 m glucose 3 mrvi pyruvate or 0.07 mivi tolrestat
(N- -(trifluoromethyl)-6-Methoxy- I -naphthalenyl] -thioxo-
methyl 1-N methylglycine) and terminated as described above
for assessment of glycolytic intermediates or as described
below for quantification of glomerular polyol and myo-inositol
content. A third set of experiments was performed on glomeruli
removed from normal rats fed standard ground chow or ground
chow containing toirestat in an amount to provide 0.2 mmol/kg
body weight/day or AL-1576 (spiro-(2,7-difluoro-9H-fluoren-
9,4'-imidazolidine)2',5'-dione) in an amount to provide --0.02
mmol/kg body weight/day for two to seven days prior to
glomerular isolation. In these experiments, glomeruli from
control rats were incubated only in 5 or 30 m glucose while
glomeruli from rats treated with tolrestat or AL-1576 were
incubated in the same buffers containing 0.07 mt tolrestat or
0.007 mivi AL-1576 added in a volume of 5 p1. After a one hour
incubation, glomeruli were extracted for assessment of glyco-
lytic intermediates (tissue + medium). In a fourth experiment,
glomeruli were obtained from kidneys of rats fed standard
ground chow or ground chow containing tolrestat as described
above, then incubated for one hour at 37°C in 2.5 ml KH buffer
containing 5 or 30 m glucose + 0.07 mivi tolrestat. Glomeruli
were allowed to settle to the bottom of the incubation tube
during the last minute of incubation, then rapidly pipetted into
a 1.5 ml microfuge tube on ice and centrifuged at 14,000 g for 30
seconds at 4°C. The remaining medium was removed and 50 1d
of 12 N perchloric acid was added to the pellet. The extract
(tissue only) was saved for determination of glomerular lactate
and pyruvate.
Metabolic and biochemical assays
Glycolytic intermediates. Five to ten minutes following addi-
tion of perchloric acid as described above, the tubes were
centrifuged, the supernatant was removed, the pH was adjusted
to --3.5, and the supernatant was assayed for fructose, Sn-
glycerol 3-phosphate, and glycolytic metabolites (glucose
6-phosphate, G6P; fructose 6-phosphate, F6P; fructose 1,6-
bisphosphate, dihydroxyacetone phosphate, and glyceralde-
hyde 3-phosphate measured together as total triose phosphates;
pyruvate, and lactate) by standard enzymatic methods [32, 331.
The pellet was saved for measurement of hydroxyproline [34] to
which all the metabolic data were normalized. Prior to fructose
analysis extracts were treated with glucose oxidase [35] to
prevent interference with measurement of fructose by high
glucose levels.
The effect of elevated glucose levels on the cytosolic ratio of
NADH/NAD was not measured directly, but was inferred
from changes in the ratio of glomerular lactate/pyruvate; the
cytosolic ratio of these metabolites is a more reliable parameter
of the cytosolic ratio of free NADH/NAD than measurement
of the pyridine nucleotides themselves in tissue extracts [19,
36]. Since, depending on the experimental conditions and
interventions performed, changes in lactate/pyruvate in the
incubation medium at the end of an incubation may not corre-
spond to the ratio of lactate/pyruvate in glomerular cytosol,
experiments were performed to verify that changes in lactate/
pyruvate in glomeruli plus medium (measured in the first three
series of experiments) did indeed reflect the direction of
changes in glomerular cytosol.
Glomerular polyol and myo-inositol. Following the one hour
incubation, glomeruli were immediately centrifuged at 4°C, the
pellet was resuspended in I ml of 0.02% sodium azide in water,
internal standard was added, and the glomeruli were heated at
100°C for 15 minutes. The glomerular extracts were deprotein-
ized with 0.3 N barium hydroxide and 0.3 N zinc sulfate,
centrifuged, and sorbitol and myo-inositol in the supernatant
were quantified (as their butyl boronate derivatives) by gas
chromatography/mass spectrometry [37]. The pellet was saved
for measurement of hydroxyproline content.
Statistical analysis. All data are expressed as means
standard deviations of untransformed data, Since all experi-
ments were performed on paired incubations, overall differ-
ences among groups for each parameter were assessed by a
repeated measures analysis of variance with the SAS general
linear-models procedure [38]. If the repeated measures analysis
of variance test indicated that differences among groups were
statistically significant at P < 0.05 for a given parameter,
pairwise comparisons were assessed by least-square means.
Because of the large variance in some parameters, a natural log
transformation of the data was performed before assessment of
differences between groups. The effects of aldose reductase
inhibitors given in vivo on lactate/pyruvate ratios in glomeruli
after incubation in 5 versus 30 m glucose were assessed using
a paired t-test.
Results
Effects of elevated glucose levels on glomerular glycolysis
In preliminary experiments (data not shown) glycolytic inter-
mediates were measured in glomeruli incubated in 5 or 50 mM
glucose for 30, 60, or 120 minutes. All glycolytic intermediates
in the 5 mii glucose incubations reached a steady state level by
60 minutes or remained constant for 120 minutes of incubation,
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Fig. 2. Glycolytic intermediates (glucose 6-
phosphate, fructose 6-phosphate, total triose
phosphates, and sn-glycerol 3-phosphate) in
glomerul, incubated for one hour at 37°C in 5.
15, or 30 mst glucose. Metabolites. expressed
as nmol/g hydroxyproline, are shown as the
mean I si (N = 7 for each glucose
concentration). Significantly different from 5
m glucose: * < 0.01, tP < 0.03.
with the exception of triose phosphates which increased 1 .6-
fold in 120 versus 30 minute incubations. Fifty millirnolars of
glucose increased G6P, F6P, triose phosphates, and lactate (but
not pyruvate) after 30 minutes of incubation (P  0.05). All of
these metabolites remained elevated throughout 120 minutes of
incubation except F6P. Pyruvate levels were significantly in-
creased at 60 and 120 minutes (P < 0.025). Based on these data,
subsequent incubations were carried out for 60 minutes.
Incubation of glomeruli for one hour in medium containing 5,
15, or 30 mrvi glucose (Figs. 2 and 3) resulted in a concentration-
dependent increase in glomerular levels/production of G6P,
F6P, total triose phosphates, and lactate (P < 0.008, 0.01. 0.02,
and 0.03, respectively). Pyruvate and snG3P levels remained
constant between 5 and 30 m glucose and the lactate/pyruvate
ratio (Fig. 3C) increased from 11.7 3.3 at 5 m glucose to 14.8
3.6 at 30 m glucose (P < 0.003). Based on the results of
these experiments, all subsequent incubations were performed
for 60 minutes in either 5 or 30 m glucose pharmacologic
agents.
Effects of pyruvate and a/dose reductase inhibitors added in
vitro on glucose-induced metabolic changes
The effects of 30 m glucose on glomerular levels/production
of glycolytic intermediates in these experiments (Figs. 4 and 5)
are consistent with those observed in the preliminary studies
(Figs. 2 and 3). Sorbitol and fructose levels were increased
significantly (P < 0.001 and P < 0.014, respectively) and
myo-inositol content decreased slightly (but insignificantly) in
glomeruli incubated in 30 versus 5 m glucose (Fig. 6).
Coadministration of 3 mrvt pyruvate with 30 m glucose was
associated with a small increase in lactate levels (statistically
insignificant vs. 30 m glucose), an —70% decrease in triose
phosphates (P< 0.001 vs. 30 mrvt glucose) and a similar —70%
decrease in snG3P (P < 0.0002 vs. 30 m glucose), but had no
effect on F6P or G6P (Figs. 4 and 5). Pyruvate also decreased
glomerular sorbitol levels by —60% (P < 0.01 vs. 30 mist
glucose) but had no effect on fructose or inyo-inositol levels
(Fig. 6).
In vitro addition of 0.07 mrvt tolrestat to 30 m glucose had no
effect on 30 mrvi glucose-induced changes in lactate. pyruvate,
lactate/pyruvate ratio, or triose phosphates (Figs. 4 and 5). In
contrast, tolrestat significantly reduced glomerular levels of
snG3P (Fig. 4D). Tolrestat also largely prevented 30 mivi
glucose-induced increases in glomerular sorbitol levels (Fig.
6A) but had no effect on fructose or myo-inositol levels (Fig. 6B
and C). While the 30 m glucose-induced increase in lactate/
pyruvate ratio was unaffected by the addition of 0.07 mivi
tolrestat in vitro (Fig. SC), the increase was abolished in
corresponding experiments with glomeruli from rats given
toirestat or AL-1576 in the diet prior to isolation of glomeruli
(Fig. 7A).
Effects of elevated g/ucose and a/dose reductase inhibitors on
cytosolic redox state of glomeru/i
To obtain a more reliable assessment of glomerular cytosolic
NADH/NAD, lactate/pyruvate ratios were measured in gb-
meruli rapidly separated from incubation medium. As shown in
Figure 7B, lactate/pyruvate ratios in S m glucose-incubated
glomeruli were almost twice those in extracts of glomeruli plus
medium (Fig. 7A). Nevertheless, the ratios increased —30%
after 60 minutes of incubation in 30 mrvi (31.2 11.6) versus 5
mM (23.8 7.5) glucose, closely corresponding to the increases
observed in tissue plus medium after the same duration of
incubation (Fig. 7A). The lactate/pyruvate in glomeruli from
rats fed ARI for seven days and incubated in 5 mrvi glucose plus
ARI was significantly lower than that in glomeruli from control
rats; 30 m glucose-induced increase in lactate/pyruvate was
prevented in 30 mrvt glucose-incubated glomeruli from ARI-fed
rats.
Metabolite levels (in medium plus glomeruli) for glomeruli
isolated from ARI-fed versus untreated rats following incuba-
tion in 5 and 30 m glucose are summarized in Figure 8.
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Elevated triose phosphate levels induced by 30 m glucose in
glomeruli from untreated rats were prevented in glomeruli from
ARI-fed rats (but not by AR! added in vitro only). snG3P levels
in 30 m glucose-incubated glomeruli were decreased by AR!
added in vitro only as well as in glomeruli isolated from ARI-fed
rats, Although lactate production by glomeruli (incubated in 30
m glucose) from ARI-fed rats tended to be lower than that by
glomeruli from controls, the difference was not statistically
significant.
Discussion
The demonstration that exposure of isolated glomeruli from
normal rats to elevated glucose levels in vitro causes a more
reduced cytosolic ratio of NADH/NAD is consistent with
corresponding effects of elevated glucose levels on cytosolic
NADH/NAD in a number of tissues from animals and in
human erythrocytes, as noted in the introductory paragraphs of
this paper. Furthermore, this glucose-induced glomerular redox
change, like that in erythrocytes, granulation tissue, and lens, is
prevented or markedly attenuated by aldose reductase inhibi-
tors [6, 18, 25—27, 39, unpublished observations]. It should be
noted that glomeruli are comprised of several different cell
types (endothelial, epithelial, and mesangial cells) and the
metabolic changes observed in the present studies reflect the
sum of the changes in all of them. On the other hand, all of these
cells are components of glomerular vessels, and the magnitude
of the metabolic changes observed supports the likelihood that
they reflect the metabolic state in a significant proportion of the
glomerular vasculature. These observations have a number of
potentially important implications for the pathogenesis of dia-
betic glomerulopathy.
Metabolic effects of elevated glucose levels
The —30% increase in lactate production in glomeruli ex-
posed to 30 versus 5 m glucose is consistent with evidence of
glucose-induced increases in lactate production in skin chamber
granulation tissue [18] and increased glycolysis in bovine retinal
endothelial cells [221,and increased lactate levels in retina and
sciatic nerve endoneurium from diabetic rats [40]. Glucose-
induced increased lactate production in all of these tissues
could be explained by the presence of hexokinase(s) with a
relatively high Km for glucose [41] or release (by elevated
glucose levels) of hexokinase inhibition by G6P [42]. The
elevated levels of G6P and F6P in 30 m glucose-incubated
glomeruli (Figs. 2 and 4) would be consistent with both possi-
bilities.
The increase in triose phosphate levels induced by 30 mM
glucose (Figs. 2, 4, and 8) is consistent with a more reduced
cytosolic ration of NADH/NAD since oxidation of GAP
(which is in equilibrium with DHAP and FDP) to 1,3 DPG is
coupled to reduction of NAD to NADH (Fig. I). Since a more
reduced cytosolic ratio of NADH/NAD favors snG3P synthe-
sis by reduction of DHAP (with NADH serving as the hydrogen
donor), the finding that snG3P levels were not elevated in 30
m glucose-incubated glomeruli raises the possibility that uti-
lization of snG3P was increased. This interpretation is consis-
tent with evidence that 30 ms't glucose increases de novo
synthesis of DAG in isolated glomeruli [21], since reduction of
DHAP to snG3P is the first step in one pathway for de novo
synthesis of DAG (Fig. 1). These observations and interpreta-
tions also are consistent with evidence that snG3P dehydroge-
nase activity is not high enough in some tissues (under some
conditions) to maintain equilibrium between its substrates
(snG3P and DHAP) [19, 43].
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Fig. 3. Effects of increasing glucose concentration (5, /5, and 30 msi
glucose) on lactate, pyruvate, and lactare/pyruvate ratio, in glomeruli
incubated for one hour at 37°C. Metabolites, expressed as nmol/fLg
hydroxyproline, are shown as the mean I si for each glucose
concentration (N = 7). Significantly different from 5 msi glucose:
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Fig. 4. Effects of 3 msx pyruvate and 0.07 mM
to/restat on glycolytic intermediates
(expressed as nmo///.tg hydroxyproline, N = 9
for each group, mean I so) in glomeruli
incubated with 30 miw glucose for one hour at
37°C (N = 9for each group). Significantly
different from 5 m glucose: * 0.001, tP
0.005, 1P  0.001, §P < 0.05. Significantly
different from 30 m glucose: liP 0.0002, ¶P
<0.006.
The increased sorbitol levels in 30 mrvt glucose-incubated
glomeruli (Fig. 6) is consistent with previous reports 112, 44]
and, together with the increased fructose levels (Fig. 6) and the
prevention of 30 m glucose-induced increase in the lactate!
pyruvate ratio by aldose reductase inhibitors, supports the
hypothesis that increased oxidation of sorbitol to fructose
contributes significantly to the more reduced cytosolic ratio of
NADH/NAD in glomeruli exposed to elevated glucose levels.
Effects of a/dose reductase inhibitors and pyruvate on
glucose-induced metabolic imbalances
Glucose-induced increases in lactate/pyruvate ratios (in gb-
meruli plus medium) were relatively unaffected by coadminis-
tration of AR! in vitro only (Fig. 5), but were prevented in
glomeruli from ARI-fed rats (Fig. 7A). These discordant find-
ings may be explained by a relatively slow rate of penetration of
glomerular cells by AR!. By the time inhibitory levels were
attained in glomeruli exposed to ARI only in vitro, it was too
late to normalize the lactate/pyruvate ratio in the medium (most
of the lactate and pyruvate are recovered in the medium rather
than in the cells). In contrast, excess intracellular sorbitol
formed before inhibition of aldose reductase activity was
achieved would still be readily oxidized to fructose, that is,
"normalized," during the latter part of the incubation. This
interpretation is consistent with evidence that sorbitol levels in
red cells and other tissues decrease rapidly following normal-
ization of glucose levels [45—47]. The observation that tolrestat
decreased tissue lactate/pyruvate ratio in glomeruli incubated in
5 mM glucose suggests that flux of glucose via the sorbitol
pathway impacts significantly on glomerular cytosolic NADH/
NAD even at physiological glucose levels.
Aldose reductase utilizes NADPH as the hydrogen donor for
the reduction of glucose to sorbitol. This reaction results in a
more oxidized ratio of NADP/NADPH (Fig. 1). In contrast,
sorbitol dehydrogenase utilizes NAD as the hydrogen accep-
tor for oxidation of sorbitol to fructose. This reaction results in
a more reduced cytosolic ratio of NADH/NAD as noted
earlier. Therefore, the 30 m glucose-induced increases in
lactate/pyruvate (Fig. 7) and their prevention by AR! appear to
be more closely linked to redox changes resulting from in-
creased oxidation of sorbitol to fructose than to reduction of
glucose to sorbitol. This interpretation is supported by several
lines of evidence. First, although (as noted earlier) the ratio of
pyridine nucleotides in cellular extracts may not accurately
reflect the cytosolic ratio of free NADH/NAD, it is notewor-
thy that 30 m glucose-induced changes in NADH/NAD in
glomerular extracts are indeed consistent with changes in
lactate/pyruvate ratio in the incubation medium (data not
shown). Second, topical application of sorbitol to granulation
tissue vessels in vivo causes vascular dysfunction, like that
induced by glucose, which is prevented by coadministration of
pyruvate but not by aldose reductase inhibitors [16, unpub-
lished observations]. Third, the ratio of lactate/pyruvate and the
levels of other metabolites (triose phosphates and snG3P)
modulated by NADH/NAD in human erythrocytes are mark-
edly increased during incubation with sorbitol or xylitol (xylitol
also is a substrate for sorbitol dehydrogenase) [39, 48], and
these increases are prevented by pyruvate [39]. The decrease in
snG3P levels (and the trend for triose phosphates to decrease,
albeit not statistically significant) in 30 m glucose-incubated
glomeruli from ARI-fed rats (Fig. 8) is consistent with the
associated normalization of the cytosolic lactate!pyruvate ratio
(Fig. 7B). The observation that snG3P levels in 30 m glucose-
incubated glomeruli from ARI-fed rats were lower than those in
5 and 30 m glucose-incubated glomeruli from control rats (Fig.
8) may reflect greater inhibition (by AR!) of synthesis than
utilization of snG3P (due to differences in oxidation/reduction
potentials and equilibrium constants of snG3P dehydrogenase
and the enzymes that utilize snG3P for lipid synthesis) [19, 43].
The pyruvate-induced decrease in triose phosphates, snG3P,
and sorbitol (Figs, 4 and 6) are consistent with corresponding
pyruvate effects on glucose-induced changes in cytosolic
NADH/NAD and on NADH/NAD modulated metabolite
levels (including sorbitol and fructose) in human red cells and in
skin chamber granulation tissue [18, 25, 39, unpublished obser-
vations]. All of these effects of pyruvate are consistent with
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Fig. 6. Effects of 3 miw pyruvate and 007 tn tolrestat on sorbitol,
fructose, and myo-inositol accumulation in glomeruli obtained from
normal rats after incubation in 30 mM glucose for one hour at 37°C (N
= 6). Results are expressed as nmol/jxg hydroxyproline and are mean
I 5D. Significantly different from 5 mtvi glucose: *p  tP C 0.014,
tP C 0.04. Significantly different from 30 mrvi glucose: §P C 0.0 14, lIP <
0.011.
oxidation of NADH to NADt by pyruvate at a rate faster than
NAD is reduced to NADH by oxidation of sorbitol to fructose
(Fig. 1). The apparent failure of pyruvate to increase fructose
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Fig. S. Effects of 3 m,w pyruvate and 0.07 mM tolrestat on lactate,
pyru vote, and lactatelpyru vote ratio in glomeruli incubated with 30 msc
glucose for one hour at 37°C. Metabolites, expressed as nmol/g
hydroxyproline, are shown for each incubation as the mean I sn (N
= 9 for each group). The amount depicted for pyruvate (B) in the 30 mrvi
glucose + 3 mM pyruvate group is an approximate value (indicated by
the —-) derived by dividing lactate produced by glomeruli by pyruvate
added to the medium. It is shown merely to indicate that addition of 3
mM pyruvate to the medium results in higher pyruvate levels than those
produced by glomerular metabolism. Significantly different from 5 mM
glucose: * C 0.001, tP 0.005.
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Fig. 7. Effects of 5 mivi and 30 m glucose toirestat on the glomer-
u/ar tissue lactat elpyru vale ratio (A) oron tissue plus medium lactate!
pyruvare ratio (B). Glomeruli used for incubation in 5 or 30 m glucose
+ toirestatwere obtained from nondiabetic rats fed tolrestat in their diet
(0.02 mmol/kg body weight) for 7 days prior to glomerular isolation.
Since these are paired observations, the lactate/pyruvate ratios from
each incubation are connected by lines. Mean I sr is also indicated.
levels in 30 m glucose-incubated glomeruli, despite a marked
reduction in sorbitol levels, may be due to the presence of
fructokinase in the glomeruli and/or in the small number of
contaminating tubules, portions of which contain large amounts
of the enzyme [49].
These observations raise several important related questions
regarding: 1) the reliability of measurements of tissue sorbitol
levels alone (without fructose measurements) as an index of
sorbitol pathway activity, 2) how much of an increase in
sorbitol pathway activity can be tolerated by cells/tissues
without pathophysiological consequences, and 3) how readily
reversible increases in sorbitol pathway activity contribute to
poorly reversible glucose- and diabetes-induced metabolic im-
balances, as well as functional and structural angiopathy (in-
cluding glomerulopathy) and neuropathy. Tissue sorbitol levels
are determined not only by intracellular glucose levels, but also
by the ratio of sorbitol dehydrogenase to aldo-keto reductase
enzyme activities [50]. Thus, if the ratio of sorbitol dehydroge-
nase to aldose reductase in a tissue is high, elevated tissue
glucose levels can markedly increase glucose metabolism via
the sorbitol pathway to fructose (Fig. I), and induce sorbitol
pathway-mediated cellular injury, with little or no increase in
tissue sorbitol content.
The level to which sorbitol pathway activity can be increased
without causing metabolic and pathophysiological conse-
quences remains unclear and may vary considerably in different
tissues. It appears likely that relatively small increases in
sorbitol pathway activity may be sufficient to cause vascular
dysfunction in many tissues. This view is supported by the
observation that in diabetic rats treated with two different doses
of an ARI (AL-1576), both of which normalized sorbitol levels
in every tissue examined, only the higher dose decreased
microalbuminuria and normalized GFR and vascular albumin
permeation in ocular tissues, sciatic nerve, and granulation
tissue [5]. These observations have important implications
regarding the interpretation of experiments in which ARI have
been reported to normalize sorbitol levels but fail to prevent
associated glucose-induced changes in protein kinase C activity
[20, 23] and diabetes-induced increases in GFR [12] and gb-
merular structural changes [12]. Differential effects of ARI on
metabolic imbalances, functional, and/or structural changes in
the same cells and tissues [23, 51—531 may reflect the differential
impact of partial normalization of cytosolic NADH/NAD on
dehydrogenase enzymes with different oxidation/reduction
potentials and equilibrium constants (and on the relative con-
centrations of their reduced and oxidized substrates).
The nature of the mechanism(s) by which transient increases
in sorbitol pathway activity may induce poorly reversible
functional and structural glomerular changes (and other vascu-
lar and neural complications of diabetes) also remains unclear.
In view of evidence linking increased tissue DAG levels (and
associated increased protein kinase C activity) to increased
sorbitol pathway activity in granulation tissue [15], it can be
postulated that transient elevations in DAG may cause much
longer lasting effects through activation and membrane associ-
ation of protein kinase C and phosphorylation of protein kinase
C substrates.
Implications of a more reduced cytosolic NADH/NAD ratio
for the pathogenesis of diabetic nephropathy
One mechanism by which increased sorbitol pathway activity
may induce poorly reversible vascular changes is by production
of metabolites capable of nonenzymatically glycating intracel-
lular constituents such as triose phosphates (which are among
the most reactive naturally occurring glycating agents in tissues
[54]) and fructose 3-phosphate and 3-deoxyglucosone [55]. The
likelihood that nonenzymatic glycation may contribute to glu-
cose- and diabetes-induced vascular dysfunction is supported
by evidence that aminoguanidine (a nucleophilic hydrazine
compound believed to prevent formation of advanced glycation
end-products [56]) prevents sorbitol-, glucose-, and diabetes-
induced increases in vascular albumin permeation [57—59],
A more reduced cytosolic ratio of NADH/NAD could
impact on at least two important pathways of lipid metabolism
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(Methods) prior to glomerular isolation versus
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Metabolite levels are expressed as a ratio of
the corresponding level in 5 msi glucose-
incubated glomeruli. The dashed line (ratio =
I) represents the metabolite level in 5 mM
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glucose-incubated glomeruli. Open circles =
30 msi glucose; open triangles = 30 mMG6P F6P TP sn-G3P P L L/P glucose + 0.07 msi AR! added to incubation
medium in vitro; closed triangles = 30 mri
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to the diet and also added to the incubation
medium (Methods). G6P = glucose 6-
"S phosphate, F6P = fructose 6-phosphate, TPi'i NS 0.005 0.002 total triose phosphates (fructose 1,6-0.002 NS NS 0.002 bisphosphate, dihydroxyacetone phosphate,
0 005 NS NS NS and glyceraldehyde 3-phosphate), snG3P =
sn-glycerol 3-phosphate, P = pyruvate, L =
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resulting in: 1) increased de novo synthesis of DAG, and 2)
impaired 3 oxidation of long chain fatty acyl CoA in mitochon-
dna. As discussed above, a more reduced cytosolic ratio of
NADH/NAD would favor glucose-induced increased de novo
synthesis of DAG and associated activation of protein kinase C
(Fig. 1) observed in isolated glomeruli exposed to elevated
glucose levels in vitro [20, 21]. The putative importance of this
cascade of metabolic imbalances is consistent with amelioration
by myo-inositol of vascular dysfunction (including increases in
GFR and in urinary excretion of !gG) in diabetic rats [8, 60],
since elevation of tissue myo-inositol levels would favor incor-
poration of DAG into phosphatidylinositol (Fig. 1), thereby
lowering DAG levels and normalizing impaired phosphatidyl-
inositol metabolism [61, 62]. This interpretation is consistent
with evidence that agonist-induced increases in DAG and
CDP-DAG (associated with breakdown of PIP2) in a variety of
tissues are prevented and/or reversed by myo-inositol [63—66].
In addition, excess cytosolic reducing equivalents (NADH)
generated by increased oxidation of sorbitol to fructose can be
transported into the mitochondria (by the malate-aspartate
shuttle). !n ischemic myocardium, an increase in mitosolic
NADH/NAD inhibits mitochondrial /3 oxidation of long-chain
fatty acyl CoA (Fig. 1) [11], which accumulate as long-chain
acyl esters of CoA and carnitine [67]. These long-chain acyl
esters, like DAG, are potent modulators of the activity of
several enzymes (including protein kinase C, Na/K-ATPase,
and Ca -ATPase) implicated in the pathogenesis of diabetic
complications. While the role of this putative cascade of meta-
bolic imbalances in the pathogenesis of diabetic glomerulopathy
remains unknown, metabolic imbalances of this nature could
explain the apparent links between elevated plasma lipid levels,
microalbuminuria, and nephropathy in diabetic humans and
animals [68—71].
In conclusion, these studies demonstrate that elevated glu-
cose levels lead to a more reduced ratio of cytosolic NADH/
NAD in glomeruli which is linked to increased flux of glucose
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via the sorbitol pathway. They also suggest several candidate
mechanisms by which a more reduced glomerular cytosolic
ratio of NADH/NAD may modulate lipid metabolism and
nonenzymatic glycation and contribute to the pathogenesis of
diabetic nephropathy. While these observations implicate in-
creased sorbitol pathway metabolism in the pathogenesis of
glomerular dysfunction in diabetic animals, further studies are
needed to elucidate the role of sorbitol pathway metabolism in
the pathogenesis of diabetic glomerutopathy in human subjects.
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Appendix. List of abbreviations
aldose reductase inhibitor
cytidine diphosphate-DAG
1 ,2-diacyl-sn-glycerol
dihydroxyacetone phosphate
1 ,3-bisphosphoglycerate
fructose 1 ,6-bisphosphate
fructose 6-phosphate
glyceraldehyde 3-phosphate
glucose 6-phosphate
Krebs-HEPES buffer
lactate
lactate/pyruvate ratio
pyruvate
phosphatidylinositol-bisphosphate
sn-glycerol 3-phosphate
total triose phosphates
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